Abstract Introduction Ulcerative colitis is an inflammatory bowel disease that causes inflammation and ulceration in the large intestines and exacerbates gut microbiome dysbiosis which leads to the development of various diseases. Six Gentlemen Decoction is a traditional Chinese medicine for treating gastrointestinal disorders and when Aucklandia and Amomum (SGDAA; Xiangsha Liujunzi Tang) are added, this further improves colitis, by relieving pain. The efficacy and safety of SGDAA intake in the treatment of ulcerative colitis was systematically evaluated and a meta-analysis conducted. Methods Randomized controlled trials (RCTs) on the use of SGDAA and colitis were retrieved from medical and scientific databases in English, Korean, and Chinese from January 1960 to October 2019. RevMan 5.3 software was used for the meta-analysis. According to study homogeneity, odds ratios(ORs) and confidence intervals of pooled RCTs were assessed by fixed or random model meta-analysis. The risk of bias was evaluated for all included studies. Results Seven studies (614 colitis patients) were included in this meta-analysis: 308 patients had SGDAA (SGDAA group) and 306 patients received conventional Western medicine or another Chinese medicine (control group). Meta-analysis of the 7 pooled RCTs showed that SGDAA was more effective for ulcerative colitis treatment (OR = 0.22, 95% CI: 0.13 ∼ 0.37; P Conclusion Oral SGDAA treatment for ulcerative colitis more than 4 weeks was superior to conventional Western medicine for the treatment of ulcerative colitis.

中文翻译：

---

六君汤加砂仁砂仁（香沙六君子汤）治疗溃疡性结肠炎：随机临床试验的系统评价和荟萃分析

摘要 介绍 溃疡性结肠炎是一种炎症性肠病，可引起大肠炎症和溃疡，加剧肠道微生物群失调，导致多种疾病的发生。六君子汤是一种治疗胃肠道疾病的传统中药，当添加奥克兰和砂仁（SGDAA；香沙六君子汤）时，可以通过缓解疼痛来进一步改善结肠炎。系统评估了 SGDAA 摄入治疗溃疡性结肠炎的有效性和安全性，并进行了荟萃分析。方法 从 1960 年 1 月至 2019 年 10 月的英文、韩文和中文的医学和科学数据库中检索关于 SGDAA 和结肠炎使用的随机对照试验 (RCT)。使用 RevMan 5.3 软件进行荟萃分析。根据研究的同质性，通过固定或随机模型荟萃分析评估汇总 RCT 的优势比（ORs）和置信区间。评估了所有纳入研究的偏倚风险。结果本荟萃分析共纳入7项研究（614例结肠炎患者）：SGDAA组308例（SGDAA组），西药或其他中药组306例（对照组）。7 项汇总 RCT 的荟萃分析表明，SGDAA 治疗溃疡性结肠炎更有效（OR = 0.22，95% CI：0.13 ∼ 0.37；P 结论 口服 SGDAA 治疗溃疡性结肠炎 4 周以上优于常规西药治疗溃疡性结肠炎的治疗。评估了所有纳入研究的偏倚风险。结果本荟萃分析共纳入7项研究（614例结肠炎患者）：SGDAA组308例（SGDAA组），西药或其他中药组306例（对照组）。7 项汇总 RCT 的荟萃分析表明，SGDAA 治疗溃疡性结肠炎更有效（OR = 0.22，95% CI：0.13 ∼ 0.37；P 结论 口服 SGDAA 治疗溃疡性结肠炎 4 周以上优于常规西药治疗溃疡性结肠炎的治疗。评估了所有纳入研究的偏倚风险。结果本荟萃分析共纳入7项研究（614例结肠炎患者）：SGDAA组308例（SGDAA组），西药或其他中药组306例（对照组）。7 项汇总 RCT 的荟萃分析表明，SGDAA 治疗溃疡性结肠炎更有效（OR = 0.22，95% CI：0.13 ∼ 0.37；P 结论 口服 SGDAA 治疗溃疡性结肠炎 4 周以上优于常规西药治疗溃疡性结肠炎的治疗。